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Even if there is not a general consensus, we consider elderly patients of 65 years old or more. The degree
of aging is extremely variable so that we can individuate different groups of patients that are different
one from the other in relation with Performance Status, the presence of other pathology, and of eventual
social discomfort.
Breast Cancer is the most common Tumor in elderly woman and it represent the ﬁrst death cause The
45% of Breast Cancer arise in women more than 65 years old and the 33% arise in women of more than 70
years old. Despite these data elderly women are often excluded from screening schedules, moreover
despite there is no evidence that breast cancer is less aggressive in elderly patient they are generally non
considered in trial studies so that they are under treated if compared to young patients that's why we
cannot observe a decrease of mortality such as in younger patients Relative survival between 5 and 10
years in patients more than 75 years old it's lesser than the one observed in younger patients (between
45 and 70 years old) maybe that's because of the incongruity in the access to sanitary structures and
because of the social and economic discomfort.
When we speak about Breast Cancer we cannot be able to leave a multidisciplinary approach out of
consideration. Patient's evaluation must be done by a group of dedicated specialists that are: Radiologist,
Pathologist, Surgeon, Radiotherapist and Oncologist. The team need to analyze all data to improve
treatment and obtain a better cosmetic result [4]. Complex cases must be discussed collectively before
surgery to obtain the best therapeutic strategy. Moreover it's strictly important patient's involvement in
treatment selection. Consensus is mandatory and it can be obtained only if the patient is well informed
about treatment phases, adverse effects, and results.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.Breast Cancer has reached in Italy such an incidence that can be
considered a very social illness and it represents the ﬁrst death
cause by cancer in women [1]. The introduction of screening
schedules [2] increased diagnosis of early stage breast cancer, thisand Experimental Medicine,
ersity of Naples, Piazza Mir-
Reginelli), antocalv@libero.it
), difrancorossella@virgilio.it
. Silvestro), gianluca.gatta@
aci), roberto.grassi@unina2.it
bianca).
by Elsevier Ltd. All rights reservedadded to therapeutic schedules that are more and more effective
improved survival [2].
When we speak about Breast Cancer we cannot be able to leave
a multidisciplinary approach out of consideration. Patient's evalu-
ation must be done by a group of dedicated specialists that are:
Radiologist, Pathologist, Surgeon, Radiotherapist and Oncologist.
The team need to analyze all data to improve treatment and obtain
a better cosmetic result [2]. Complex cases must be discussed
collectively before surgery to obtain the best therapeutic strategy.
Moreover it's strictly important patient's involvement in treatment
selection. Consensus is mandatory and it can be obtained only if the
patient is well informed about treatment phases, adverse effects,
and results..
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In the order to select the most suitable treatment for each pa-
tient, we need to know these Data:
1.1. Clinical data
 Tumor location
 Tumor size
 Connection to the nipple
 Connection to the skin and the thorax wall
 Stage of regional nodes1.2. Instrumental data
Mammography allows neoplasm identiﬁcation and the deﬁni-
tion of neoplasm size and characteristics giving useful knowledge
for treatment identiﬁcation.
If preserving surgery is considered, we need to know these
radiological data (referred to bilateral mammography) [3].
 Tumor location
 Tumor size
 Presence of multiple Tumors focuses in the same quadrant or in
different ones
 Tumor contact with the nipple
 Tumor contact with the Thorax wall
 Distribution and location of micro-calciﬁcations and dimension
of interested area.
Mammographic results must be described according to BiRRADS
nomenclature [4] and combined with other instrumental exami-
nation executed.
Ultrasounds is complementary to mammography and must be
executed in patients whose breast is particularly dense in the order
to deﬁne with accuracy useful data for a feasible treatment [5].
Magnetic Resonance, according to Radiologist indication, could
be useful when Mammography and Ultrasounds can't be easily
interpreted [6].
1.3. Surgical data
Preserving Surgery is the suggested treatment approach for
small size breast cancer although we have to consider some
particular situations:
 Patients with two or more neoplasms located in different
quadrants or with spread micro-calciﬁcations can't be submit-
ted to preserving surgery. When there is the presence of
different nodules in the same quadrant we have to analyze each
case to ﬁnd the right indication.
 Preserving surgery can be considered in relation with breast
volume if there is a 4e5 cm tumor mass.
 Preserving surgery is not suggested when there are big size
tumors in small breasts because cosmetic result could be not
satisfactory [7].
 If positive resection margins persist after wide excision, re-
resection is suggested.I's strictly important to give a complete description of
intervention. It must be speciﬁed:
✓ Which kind of intervention has been executed, with
deepened data about surgical rehash [8].
✓ Presence of metal clips to the sides of tumor bed that can
help the individuation of tumor bed itself when aradiation therapy boost is needed in order to establish
beams direction [10,11]. Clips are helpful above all when
patient is submitted to surgical remodeling.
✓ Kind of nodal dissection.
When Radical Mastectomy is the surgical option we need to
know:
 Which kind of mastectomy has been executed
 Which kind of nodal dissection has been executed
 Neoplasm connection to the skin, chest wall, pectoral
muscle
 Potential presence of metal clips
 Post-surgical complications
 Kind of reconstruction (if executed)Alternative therapeutic approach might consist in injecting the
patients with autologous endothelial progenitor cells, to accelerate
tissue revascularization and prevent a surgical approach [9e13].
Unfortunately, the therapeutic feasibility of such a strategy would
require the elucidation of the biological properties of these rathe
promising cells, which is far from being fully achieved.
1.4. Histological data
Macroscopical data:
 Tumor size and surgical cut size
 Connection between tumor and surgical margins
 Neoplasm connection to the skin, chest wall, pectoral muscle
Microscopical and laboratory data:
 Histological kind and histological grade
 State of Hormonal Receptors
 Multi focal disease
 Excision margin involvement, grade of involvement itself
 Presence and extension of IN SITU DESEASE
 Lymphatic and/or Vascular involvement
 Number and level of resected nodes, number of positive nodes
and extra capsular extension [11,12]
 HER-2 expression
 Reproducing activity (Ki67%, MIB-1).
All these data seems to be very important above all to get the
right eventual post-surgical treatment that is Radiotherapy treat-
ment to achieve local control of disease and Chemotherapy to reach
general control.
2. Radiotherapy indication
2.1. Invasive carcinoma
Invasive Breast Cancer represent the 70e75% of all breast tu-
mors and ductal Carcinoma is the 70e80% of all histological pre-
sentations. In more than 80% of patients with breast cancer
Preserving surgery is feasible.
Whole Breast Irradiation is the gold standard in post-surgical
preserving treatment in fact it decrease local recurrence of 75% if
compared to surgery alone [14e16]. So that we can say that Post-
operative Irradiation is mandatory when conservative surgery has
been executed-
There are some speciﬁc conditions in which post Mastectomy
Radiotherapy treatment is needed:
 Tumor size is more than 5 cm independently by node stage
[17e23]
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independently by node stage [21]
 4 or more axillary nodes involved [17,18,20,21]
 Patients with positive resection margins or close margins
(<2 mm) [17,22]
In post-surgical treatment Whole breast must be irradiated,
such as whole chest wall mast be treated after Mastectomy in those
cases we have just exposed. Supraclavicular Nodes need to be
treated when axillary nodes are involved, in T3eT4 tumors inde-
pendently by nodes involvement and in T1eT2 tumors when 4 or
more axillary nodes are involved.
After preserving surgery Breast gland can be submitted to a
conventional treatment (1.8e2 Gy/die in 5 fractions per week to the
whole dose of 50e50.4 Gy) or to Hypofractionated schedules that
are shown to be equal in terms of efﬁcacy by the Canadian Study
[23]. It is known that the most part of relapses occur in the tumor
bed it's common practice the delivery of a supplementary dose
(boost) to the tumor bed (2 Gy/die to 10 Gy) [24,25]. When resec-
tion margins are involved by the disease a major boost dose is
needed (between 10 and 20 Gy). After mastectomy whole chest
irradiation will be needed: total dose of 50.4 Gy (1.8 Gy/die).
2.2. Non invasive and microinvasive carcinoma
In situ Carcinoma represents the 30% of all breast Carcinomas
and several data suggest that it is a not mandatory precursor of
Invasive Carcinoma. In fact In Situ carcinoma hides all molecular
peculiarity of the Invasive form [26e28].
Common treatment is Preserving Surgery that decrease the risk
of local relapse [29e34]. Radiotherapy schedule is represented by
whole breast irradiation, recommended dose is 50e50.4 Gy with
conventional fractionation (1.8e2 Gy per fraction). It's still
controversial the use of a boost on tumor bed.
Waiting for results boost can be proposed in women younger
than 45 years old with high grade ductal carcinoma.
Mastectomy is the elected treatment when DCIS is located in
different quadrants of the same breast, when tumor size is more
than 4 or 5 cm, when there are spread micro-calciﬁcations and
when there are not adequate margins after preservative surgery.
There is no indication to axillary nodes dissection and also there
is no indication to sentinel lymph node biopsy.
Lobular In Situ Carcinoma has only surgery indication [35e37].
Such as the invasive Carcinoma, treatment approach for
Microinvasive Carcinoma is represented by preserving surgery or
mastectomy (when needed) including Sentinel lymph node
dissection. After conservative surgery RT treatment is mandatory
but there is no indication to postoperative RT treatment after
Mastectomy.
3. Our experience
From January 2011 to May 2014 we enrolled 120 patients, me-
dian age 71 years old, Karnowsky Performance Status was 90%.
Three patients were affected by bilateral Breast Cancer.117 patients,
including patients with bilateral disease (97.5%) were submitted to
preserving surgery, and 3 patients (2.5%) underwent radical mas-
tectomy. The 75% (90) of patients were submitted to axillary node
dissectionwhile 25% (30 patients) underwent Sentinel lymph-node
dissection. The most represented Histology was Invasive Ductal
Carcinoma (67.5%) followed by In Situ Carcinoma (22.5%), Invasive
Lobular carcinoma (20%) and Micro-invasive Carcinoma (1%).
Regarding pathological stage 67.5% were T1 neoplasms, 7.5%
were T2 and 2.5% were T4 neoplasms; no T3 neoplasms were
observed, the remaining 22.5% were In Situ Disease. Medianinvolved nodes were15, and only in Three cases we observed sur-
gical positive margins. Only one of all 120 patients was triple
negative the remaining of them all had positive hormone receptors.
The 87.5% of patients (105) underwent chemotherapy treatment
and only one needed to suspend chemotherapy schedule due to
kidney failure. The 40% of patients underwent biological chemo-
therapy treatment with Herceptin.
All of these patients except the one with hormone receptors
unexpressed underwent to hormonal schedules treatment.
As we can see all these patients were submitted to the same
treatment schedules reserved to younger patients, none of them
was considered too old to underwent a complete treatment. They
were evaluated in our radiotherapy structure and all of them un-
derwent Radiotherapy treatment.
Before to start treatment schedule all patients were submitted
to CT Scan to check the target volume, surgery scar hasmarkedwith
a metal strand so that the tumor bed could be easily individuated.
In fact all patients submitted to preserving surgery did not present
metal clips on tumor bed. Patients submitted to chemotherapy
schedules underwent Cardiac Ultrasounds to evaluate ejection
fraction before to start Radiotherapy.
The 90% (108) of patients underwent to conventional radio-
therapy treatment: whole breast was treatedwith opposite tangent
beams to a whole dose 50 Gy, then a supplementary dose was
delivered to tumor bed 2 Gy/die 5 days a week to a total dose of
10 Gy. The complete absorbed dose was of 60 Gy.
The10% of patients [10] underwent whole breast irradiation for a
total dose of 50 Gy 2 Gy/die, 5 days a week.
Only one patient was submitted to simultaneous chest wall and
supraclavicular nodes irradiation.
Patients underwent clinical examination once a week: skin re-
action, breast gland solidity, hematologic toxicity were evaluated.
All patients ended RT treatment, 46.8% of acute skin toxicity was
G1 (according to RTOG Scale), 22.5% was grade G2 and 2.5% was
grade G3. Skin toxicity seemed not to be connected to previous
chemotherapy treatment.
At ﬁrst follow-up all patients were disease free, only one patient
died for cardiovascular accident. Actually 92% did not present sig-
nals of local recurrence, 4.2% are died by different disease and 3%
have spontaneously suspended follow-up trials. Thanks to phone
contact we know that 3 of them have good local control and one of
them is died by cardiovascular accident.
In conclusion we can say that in our experience elderly patient
can be easily treated with the same treatment schedules reserved
to younger patients. Even if it's really difﬁcult to have a long-term
follow-up due to advanced patient's age we established to com-
plete conserving surgery with RT treatment.
All patients sustained a conventional treatment Gy/die 5 days a
week to whole breast to a total dose of 50 Gy, followed by an addi-
tional dose of 10Gy delivered to tumor bed, local control at 3 years is
94.2% and acute skin toxicity is Grade 1 in 46.8%. The 92% of patient
had complete solution of skin toxicity one year after treatment.
In the order to obtain a more feasible RT treatment for elderly
patients from April 2014 we have started a new radiotherapy
schedule for elderly patients. Ten patients, median age 70, T1 N0
M0 were submitted to Hypo-fractionated RT schedule 3.75 Gy, 5
days a week for 16 days to a total dose of 60 Gy. First results are
encouraging, in fact acute skin toxicity is G1 in 40% of cases, G2 in
30% of cases and G3 in 30% of cases. But we need more time and
more enrolled patients to obtain a substantial result.
4. Management of breast cancer in elderly patients
Even if there is not a general consensus, we consider elderly
patients of 65 years old or more. The degree of aging is extremely
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are different one from the other in relation with Performance Sta-
tus, the presence of other pathology, and of eventual social
discomfort [38].
Breast Cancer is the most common Tumor in elderly woman and
it represent the ﬁrst death cause.
Senescence is characterized by several oxidative stress induced
diseases like cancer, diabetes, neurodegenerative and cardiovas-
cular [39,40]. Oxidant molecules like NO (Nitric oxide) and ROS
(Reactive oxygen species) are overproduced in response to drugs,
chemicals, high-caloric diets, exercise and other stress agents [41].
The 45% of Breast Cancer arise inwomenmore than 65 years old
and the 33% arise inwomen of more than 70 years old [42]. Despite
these data elderly women are often excluded from screening
schedules [43,44], moreover despite there is no evidence that
breast cancer is less aggressive in elderly patient they are generally
non considered in trial studies so that they are under treated if
compared to young patients that's why we cannot observe a
decrease of mortality such as in younger patients [45,46]. Relative
survival between 5 and 10 years in patients more than 75 years old
it's lesser than the one observed in younger patients (between 45
and 70 years old) maybe that's because of the incongruity in the
access to sanitary structures and because of the social and eco-
nomic discomfort [45].
The 40% of elderly patients presents a co-morbidity at the
moment of the diagnosis despite analysis show that the most of the
elderly patients can tolerate a suitable therapy [46]. A correct
therapeutic approach would be apart from the age and include a
multidisciplinary assessment.
Diagnosis is made thanks to the same procedures used in young
women. Mammography taking advantage of contrast of adipose
tissue, that is mostly represented in old women breast gland, easily
allows tumors diagnosis even when their size is really small.
Diagnostic accuracy is near to 100%. Usually women over 70 years
old are not included in screening schedules in fact till now there are
not great evidences that suggest the utility of screening in women
over 70 years old. According to American Society of Geriatrics and
to Italian Consensus Conference, spontaneous screening must be
selected act on performance status, physiological age and life ex-
pected of each woman [47e49].
Lesions that can be submitted to surgery must be operated,
instead when patients cannot bear total anesthesia or deep seda-
tion it's possible to execute the excision of the neoplastic lesion
with local anesthesia.
Recommendations to preserving surgery or mastectomy are the
same adopted for young women, of course it's strictly important to
consider patient's possibility to be submitted to Radiotherapy
treatment when preserving surgery is selected [50]. Axillary node
dissection must be done only when there is evidence of positive
nodes, the Sentinel Lymph-node dissection is a lesser invasive
practice so that it can be easily executed. When Biopsy is positive
axillary irradiation can represent an option to axillary node
dissection. An EORTC study named AMAROS compared axillary
dissection to axillary and median supraclavicular region Radio-
therapy and ﬁrst results seems to indicate Radiotherapy superiority.
Early Breast Cancer Trialists Colaborative Group Meta-Analysis
[51] showed that post preservative surgery RT treatment decrease
local failure risk and produce beneﬁt to survival independently
from age. Nevertheless the absolute beneﬁt to survival is relative in
elderly patients because almost all these patients presents other
pathologies in addition to Breast cancer. However till now does not
exist a speciﬁc indication suggesting that there is a group of pa-
tients in which we can avoid RT treatment after preservative sur-
gery [52]. Boost to the tumor bed is considered an optional
treatment.In Those patients could be a treatment option the use of
Hypofractionated schedules, in fact local failure and disease free
survival are the same obtained with conventional schedules
without a signiﬁcant increase of severe and late adverse effect
[53e60]. Another choice is represented by Partial breast irradiation
that is the irradiation of the tumor bed with 1 cm of expansion.
Patients affected by advanced breast cancer tumors must be sub-
mitted to mastectomy if performance status and presence of other
pathologies allow the execution of this surgery [61].
Hormonetherapy is considered adjuvant treatment for women
with positive receptors. Chemotherapy must be delivered in
selected cases act on valuation of absolute beneﬁt for each patient
[62e71].
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